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OBJECTIVES The purpose of this study was to evaluate the approach of intravascular ultrasound
(IVUS)-guided percutaneous transluminal coronary angioplasty (PTCA) with spot stenting
(SS) for the treatment of long coronary lesions.
BACKGROUND Treating long coronary lesions with balloon angioplasty results in suboptimal short- and
long-term outcomes. Full lesion coverage with traditional stenting (TS) has been associated
with a high restenosis rate.
METHODS We prospectively evaluated a consecutive series of 130 long lesions (15 mm) in 101 patients
treated with IVUS-guided PTCA and SS. The results were compared with those of TS in a
matched group of patients. Coronary angioplasty was performed with a balloon to vessel ratio
of 1:1, according to the IVUS media-to-media diameter of the vessel at the lesion site, to
achieve prespecified IVUS criteria: lumen cross-sectional area (CSA) 5.5 mm2 or 50% of
the vessel CSA at the lesion site. The stents were implanted only in the vessel segment where
the criteria were not met.
RESULTS In the SS group, stents were implanted in 67 of 130 lesions, and the mean stent length was
shorter than that of lesions in the matched TS group (10.4  13 mm vs. 32.4  13 mm, p 
0.005). The 30-day major adverse cardiac event (MACE) rate was similar (5%) for both
groups. Angiographic restenosis was 25% with IVUS-guided SS, as compared with 39% in
the TS group (p  0.05). Follow-up MACE and target lesion revascularization rates were
lower in the SS group than in the TS group (22% vs. 38% [p  0.05] and 19% vs. 34% [p 
0.05], respectively).
CONCLUSIONS Intravascular ultrasound-guided SS for the treatment of long coronary lesions is associated
with good acute outcome. Angiographic restenosis and follow-up MACE rates were
significantly lower than those with TS. (J Am Coll Cardiol 2001;38:1427–33) © 2001 by the
American College of Cardiology
Treatment of long coronary lesions with plain balloon
angioplasty has traditionally yielded poor immediate and
long-term results (1,2). Coronary stents implanted in focal
lesions in large vessels (3.0 mm) result in lower restenosis
rates, as compared with balloon angioplasty (3,4). However,
lesion length is an independent predictor of in-stent resten-
osis (5,6). Because improvements in stent implantation
techniques and postprocedural pharmacologic management
(7–9) have led to the broader application of coronary
stenting in more complex lesions, the optimal approach for
long lesions remains to be defined. Full lesion coverage with
a stent from the proximal to distal normal segment has
improved the immediate outcome, but has been associated
with suboptimal long-term result (10,11). Stent length and
the number of stents have been implicated as important
predictive factors for restenosis in a number of studies
(5,12–18). Pooled data from four clinical trials using a
new-generation multicellular stent design stressed the im-
portance of stent length, independent of postprocedural
lumen gain, as a key predictor for in-stent restenosis (19).
In an effort to demonstrate the optimal intervention in
long lesions, we introduced a new approach for the treat-
ment of them. Intravascular ultrasound (IVUS)-guided
percutaneous transluminal coronary angioplasty (PTCA)
with spot stenting (SS) is a synergistic strategy employing
PTCA, IVUS and stenting for the treatment of long lesions.
This technique minimizes the need for stenting, with use of
shorter stent lengths. Stents are only placed in the particular
segments of a lesion where the luminal result does not meet
prespecified IVUS criteria after balloon angioplasty.
METHODS
Study design and patient group. This prospective study
was performed at Centro Cuore Columbus, Milan, Italy. All
patients with angiographically significant coronary lesions
referred for a coronary intervention were screened for
inclusion. Patients with an acute myocardial infarction
within the last 48 h were excluded. Any lesion with an
angiographic length 15 mm and diameter stenosis 70%
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and located in a native coronary artery with a reference
vessel size 3.5 mm was eligible for this study. A total of
101 consecutive patients with 130 lesions qualified and was
treated with IVUS-guided PTCA and SS. A comparison
was undertaken with a group of matched patients who were
treated with a traditional stenting (TS) approach in which
the lesion was fully covered from the proximal to distal
normal segment. The two groups were matched in terms of
clinical and angiographic variables. The matching process
was performed as follows: all patients with stented lesions
15 mm with angiographic follow-up were screened for
enrollment into the control group (TS). The first step in the
process was to match for the reference vessel diameter and
lesion length. All lesions within 0.05 mm of the reference
vessel diameter of vessels in the SS group and within 2 mm
of the lesion length were placed in the control group. Then,
the left ventricular ejection fraction, which had to be within
0.05, was matched. The next step was to match for age,
which had to be within2 years. Finally, there had to be an
equal number of patients in each group with diabetes and
unstable angina. To lower any possible bias, the first patient
who satisfied the matching characteristics was entered from
the initial group into the final TS group. This matching
process resulted in a selection of 121 patients with 143
lesions in the TS group, to be compared with the SS group.
Intravascular ultrasound-guided PTCA with SS. Pa-
tients with long lesions (15 mm) were initially treated
with PTCA. Baseline IVUS measurements were performed
at the diseased segment of the artery. For the initial PTCA,
the balloon size was selected according to the media-to-
media diameter at the lesion site, so that the balloon to
vessel ratio was 1:1. The lesion was predilated if it was
severe enough to prevent pre-intervention IVUS evaluation.
After the initial intervention, IVUS was performed. The
procedure was complete if the treated segment satisfied
either of the following two success criteria: 1) lumen
cross-sectional area (CSA) 50% of the vessel at the lesion
site, and 2) minimal lumen CSA 5.5mm2.
If any segment of the treated vessel did not meet either of
these criteria, the operator could proceed with further
balloon dilation or stenting. The stent length to be used had
to be the shortest length necessary to cover only the
segments of the lesion, in which the two aforementioned
IVUS success criteria were not satisfied.
These success criteria did not take into account the
presence of a dissection, as long as the true lumen CSA met
the aforementioned IVUS criteria and angiographic
Thrombolysis In Myocardial Infarction flow grade 3 was
present. Intravascular ultrasound was performed at the end
of the procedure to ensure achievement of the IVUS success
criteria and to document the final lumen dimensions.
Coronary stenting was performed using stents of slotted
tubular or ring design. During the procedure, heparin was
given to maintain an activated clotting time between 250
and 300 s. Patients were treated with aspirin, 325 mg/day,
and ticlopidine, 250 mg twice daily, started at least on the
day of the procedure.
Angiographic analysis. Coronary angiography was per-
formed in a routine manner. Patients received intracoronary
nitroglycerin (200 g) before the initial and final angio-
grams to achieve maximal vasodilation. Vessel size and
lesion length was visually estimated at the time of the
procedure. Quantitative coronary angiography (QCA) was
performed after the procedure, using a computer-based
QCA-CMS system, version 4.0 (MEDIS Medical Imaging
Systems Inc., Leiden, The Netherlands), with the dye-filled
catheter as a reference. The reference vessel diameter,
minimal lumen diameter, percent diameter stenosis and
lesion length were measured at baseline and on the final
angiogram. The interpolated reference diameter was con-
sidered as the reference segment diameter. Lesion length
was defined as the distance from the proximal to distal
segment of the lesion site. The lesions were characterized
according to the modified American College of Cardiology/
American Heart Association classification (20). Long le-
sions were defined as a single continuous narrowing
15 mm in length. Dissections were recorded and classified
according to the National Heart, Lung and Blood Institute
type (21).
IVUS equipment and measurements. Intravascular ultra-
sound imaging was performed using a 3.2-F Monorail
system with a 30-MHz transducer-tipped catheter (Ultra-
cross 3.2, Boston Scientific Corp., Sunnyvale, California).
All images were obtained with an automatic pullback system
at 0.5 mm/s. The position of the catheter on fluoroscopy
was used to correlate the angiographic and ultrasound
images. Data were stored on 0.5-in. super VHS videotape.
On-line quantitative measurements were performed during
the procedure. The lesion site with the smallest lumen area
was selected for measurement of each pass of the IVUS
catheter. Side branches, calcium and perivascular structures
were used for comparing IVUS runs. Reference lumen
CSAs were measured proximal and distal to the treated
segment in the closest, most normal appearing segments.
The average reference lumen CSA was calculated as the
mean value of the proximal and distal reference lumen
CSAs.
Abbreviations and Acronyms
BENESTENT  BElgian NEtherlands STENT
CK  creatine kinase
CSA  cross-sectional area
ECG  electrocardiogram
IVUS  intravascular ultrasound
MACE  major adverse cardiac event
PTCA  percutaneous transluminal coronary
angioplasty
QCA  quantitative coronary angiography
QMI  Q-wave myocardial infarction
SS  spot stenting
TLR  target lesion revascularization
TS  traditional stenting
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Follow-up. Clinical follow-up was obtained approximately
six months after the procedure and every six months
afterward by telephone or direct patient interview. Angio-
graphic follow-up was planned and encouraged for each
patient.
Definitions. A major adverse cardiac event (MACE) was
defined as any death, myocardial infarction or target lesion
revascularization (TLR). Target lesion revascularization was
defined as any repeat percutaneous intervention or coronary
artery bypass graft surgery performed to treat the index
lesion. A diagnosis of Q-wave myocardial infarction (QMI)
was made when there was documentation of new pathologic
Q waves (0.04 s) on electrocardiogram (ECG) in con-
junction with an elevation in creatine kinase (CK) greater
than twice the normal value, with a positive CK-MB
fraction. A diagnosis of non-QMI was made when an
elevation of CK greater than twice the normal value, with a
positive CK-MB fraction, was documented without devel-
opment of new pathologic Q waves on the ECG.
Statistical analysis. Statistical analysis was performed us-
ing the StatView statistical package (StatView version 5.0,
Abacus Concepts Inc., Berkeley, California). Continuous,
normally distributed data were expressed as the mean
value  SD. A comparison of continuous variables between
the groups was performed by using the unpaired Student t
test. Subgroup comparisons of categorical variables were
performed by using the chi-square test. Differences were
considered statistically significant at p  0.05.
RESULTS
Patient characteristics. Patient characteristics for the two
groups are shown in Table 1. There was no significant
difference between the two groups in terms of baseline
patient characteristics.
Angiographic and procedural variables. The angio-
graphic and procedural characteristics of the two groups are
shown in Table 2. There were no significant differences
between the SS and TS groups in terms of treated vessel,
lesion location, lesion type and presence of calcium or total
occlusions. Complex lesions (type B2 or C) comprised the
majority of the lesions in both groups. Of the 130 lesions
treated with SS, 67 (52 patients) required stenting, because
they did not meet the IVUS criteria for IVUS-guided
balloon angioplasty.
The final balloon size, balloon/artery ratio and maximal
inflation pressure were similar between the two groups (p 
NS). The mean stent length was significantly shorter in the
SS group (10.4  13 mm vs. 32.4  13 mm, p  0.005).
Calculation of the average stent length for the SS group
included all of the lesions, on an intention-to-treat basis
(n  130). However, only 67 lesions in this group actually
required a stent. The calculated mean stent length for this
subgroup of patients with 67 lesions is 20.2  12 mm; the
median stent length was 16 mm. When comparing this
subgroup of 67 lesions with those of the patients in the TS
group, there was still a significant difference in stent length
(p  0.005).
Glycoprotein IIb/IIIa inhibitors were used in three pa-
tients in the SS group and in 11 patients in the TS group.
A typical example of a long lesion treated with the SS
approach is shown in Figure 1.
QCA analysis. The QCA measurements before and after
the intervention are shown in Table 3. At baseline, the only
significant differences between the SS and TS groups were
Table 1. Patient Characteristics
SS Group
(n  101)
TS Group
(n  121)
p
Value
Age (years) 59.8  10 58.1  10 0.21
Male 90 (89%) 113 (92%) 0.48
Risk factors
Hypertension 54 (53%) 68 (56%) 0.78
Hypercholesterolemia 61 (60%) 80 (65%) 0.48
Diabetes 11 (11%) 13 (11%) 0.99
Smoker 69 (68%) 79 (65%) 0.50
Family history 57 (56%) 62 (51%) 0.42
Previous MI 53 (53%) 65 (53%) 0.99
Previous PTCA 35 (35%) 37 (31%) 0.56
Previous CABG 12 (12%) 14 (12%) 0.99
LVEF (%) 60  11 63  13 0.11
Unstable angina 25 (25%) 31 (25%) 0.99
Multivessel disease 72 (72%) 80 (66%) 0.63
Data are presented as the mean value  SD or number (%) of patients.
CABG  coronary artery bypass graft surgery; LVEF  left ventricular ejection
fraction; MI  myocardial infarction; PTCA  percutaneous transluminal coronary
angioplasty; SS  spot stenting; TS  traditional stenting.
Table 2. Angiographic and Procedural Characteristics
SS Group
(n  130)
TS Group
(n  143)
p
Value
Treated vessel
LAD 60 (46%) 75 (53%) 0.11
RCA 38 (29%) 42 (29%)
LCx 32 (25%) 26 (18%)
Lesion site
Ostial 4 (3%) 5 (4%) 0.13
Proximal 49 (38%) 46 (32%)
Mid-vessel 58 (45%) 81 (56%)
Distal 19 (14%) 11 (8%)
AHA/ACC lesion type 0.21
B1 32 (25%) 46 (32%)
B2 56 (43%) 64 (45%)
C 42 (32%) 33 (23%)
Calcified lesion 30 (23%) 29 (20%) 0.65
Total occlusion 11 (8.5%) 4 (3%) 0.06
Stent length (mm)* 10.4  13 32.4  13 0.005
Stent length (mm)† 20.2  12 32.4  13 0.005
Final balloon size (mm) 3.56  0.5 3.59  0.5 0.49
Final B/A ratio (mm) 1.23  0.12 1.22  0.12 0.62
Maximal inflation
pressure (atm)
14.1  3.6 14.0  3.0 0.65
*This mean value includes all lesions in the SS group, on an intention-to-treat basis
(n  130). †This average includes only the lesions in the SS group that did receive a
stent (n  67). Data are presented as the number (%) of lesions or the mean value 
SD.
AHA/ACC  American Heart Association/American College of Cardiology;
B/A  balloon to artery ratio; LAD  left anterior descending coronary artery;
LCx  left circumflex coronary artery; RCA  right coronary artery; SS  spot
stenting; TS  traditional stenting.
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the minimal lumen diameter and percent diameter stenosis,
representing unfavorable lesion characteristics for the SS
group. There was a trend toward a greater acute gain in the TS
group as compared with the SS group (p  0.06). The stent
length to lesion length ratio was significantly higher in the TS
group (0.79  0.4 vs. 1.3  0.5, respectively; p  0.0001).
Procedural outcome and clinical events. Procedural out-
come and 30-day events are shown in Table 4. There was no
significant difference between the two groups in terms of
procedural complications. Cumulative 30-day MACE
(death, coronary artery bypass graft surgery, QMI and
non-QMI) occurred in five patients (5%) in the SS group
and in six patients (5%) in the TS group. Residual angio-
graphic dissections were left untreated in 51 lesions (39%) in
the SS group and in 12 lesions (8%) in the TS group (p 
0.0001). Most of the untreated dissections (82%) were type
B in both groups. There was no significant difference in the
rate of procedural complications between the lesions with
residual dissection and those without dissection, including
acute and subacute thrombosis (0 [0%] vs. 2 [0.9%] and 1
[1.6%] vs. 1 [0.4%], respectively).
Angiographic and clinical follow-up. Six-month angio-
graphic and clinical follow-up data are presented in Table 4.
Clinical follow-up data were obtained for all patients in
both groups. The angiographic follow-up rate at six months
was 84% in the SS group.
Figure 1. An example of intravascular ultrasound (IVUS)-guided spot stenting (SS). (A) Preprocedural angiogram and IVUS images of a long lesion in
the intermediate branch. The IVUS catheter could not cross the distal part of the lesion. (B) After balloon angioplasty. Angiogram and IVUS image after
dilation with a 3.5  20 mm balloon. Intravascular ultrasound revealed a dissection and suboptimal dilation at the lesion site (74% residual stenosis).
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DISCUSSION
IVUS-guided PTCA with SS. The approach of IVUS-
guided PTCA for the treatment of coronary lesions has
shown promising results. In the CLinical Outcomes with
Ultrasound Trial pilot trial (22), IVUS guidance was used to
optimize PTCA results. Larger balloon sizes were required
in 73% of lesions, despite an optimal angiographic result.
This oversized balloon in PTCA resulted in significantly
larger final minimal lumen diameters, without increased
rates of significant dissections or ischemic complications. In
our study, despite the use of stents in only about half of the
lesions treated, the average acute gain achieved was 1.94 
0.77 mm. This is comparable to the acute gain achieved in
the stent arms of the BElgian NEtherlands STENT (BE-
NESTENT) trial and the STent REStenosis Study—
1.40  0.44 mm and 1.72  0.46 mm, respectively (3,4).
The Washington Hospital Center compiled a prospective
registry of IVUS-guided balloon angioplasties utilizing
balloons sized according to the media-to-media diameter, as
determined by IVUS (23). The one-year TLR rate was 8%
in the PTCA group, as compared with 16% in the stent
group (p  0.01). In approximately half of the patients
treated with IVUS-guided PTCA, stent implantation could
be avoided without increasing acute complications or late
adverse outcomes.
In the randomized Strategy for Intracoronary ultrasound-
guided PTCA and Stenting trial (24), a total of 269 patients
with focal lesions were randomized to IVUS-guided provi-
Figure 1. (C) After stent implantation of a 16-mm-long NIR stent. The angiogram and IVUS image show a dissection distal to the stent; the lumen at
this site is acceptable (48% residual stenosis by IVUS), and no further stenting was performed. AS  area stenosis; LA  lumen area; LD  lumen
diameter, VA  vessel area; VD  vessel diameter.
Table 3. Quantitative Angiographic Measurements
SS Group
(n  130)
TS Group
(n  143)
p
Value
Before procedure
Reference artery diameter (mm) 2.95  0.48 2.98  0.48 0.39
Minimal lumen diameter (mm) 0.75  0.43 0.88  0.40 0.01
Stenosis (%) 75  14 71  11 0.01
Lesion length (mm) 26.5  9.8 25.0  8.7 0.17
After procedure
Reference artery diameter (mm) 3.12  0.50 3.19  0.50 0.26
Minimal lumen diameter (mm) 2.70  0.66 2.99  0.48 0.01
Stenosis (%) 14.2  16 5.8  11 0.01
Early gain (mm) 1.94  0.77 2.09  0.59 0.06
Stent length/lesion length ratio 0.79  0.40* 1.3  0.46 0.0001
*This mean value includes only the stented lesions from the SS group (n  67). Data
are presented as the mean value  SD.
SS  spot stenting; TS  traditional stenting.
Table 4. Early and Late Outcomes
SS Group
(101 pts,
130 lesions)
TS Group
(121 pts,
143 lesions)
p
Value
Untreated dissection 51 (39%) 12 (8.3%) 0.0001
Type A 3 2
Type B 42 7
Type C 6 3
Acute thrombosis 0 (0%) 2 (1.4%) 0.49
Subacute thrombosis 1 (0.8%) 1 (0.7%) 0.99
Procedural non-QMI 2 (2%) 3 (2.5%) 0.94
Procedural QMI 2 (2%) 3 (2.5%) 0.94
CABG 1 (1%) 1 (0.8%) 0.99
Death 0 (0%) 0 (0%) 0.99
30-day MACE 5 (5%) 6 (5%) 0.99
6-month MACE 22 (22%) 46 (38%) 0.05
Restenosis 27 (25%) 55 (39%) 0.05
TLR 25 (19%) 48 (34%) 0.05
Data are presented as the number (%) of patients or lesions.
MACE  major adverse cardiac event; pts  patients; QMI  Q-wave
myocardial infarction; TLR target lesion revascularization; Other abbreviations as in
Table 1.
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sional stenting or standard angiographic guidance. Stenting
was performed in 50% of lesions in both groups. Intra-
vascular ultrasound-guided provisional stenting improved
the two-year clinical results.
On the basis of these concepts, we modified the IVUS-
guided PTCA approach to include the SS technique for the
treatment of long lesions. The shortest possible stent length
was used to optimize the results, but only in the segments of
a long lesion where the lumen dimensions did not meet
prespecified IVUS criteria. The rationale behind this ap-
proach is avoidance of full-lesion stent coverage of long
segments, for which restenosis rates are expected to be high
(12–16). Stent length may exacerbate neointimal hyperpla-
sia.
An unsatisfactory angiographic result, which would nor-
mally lead to additional stenting, when evaluated by IVUS,
may be considered as acceptable. This decision is based on
true lumen evaluation rather than angiographic silhouette
assessment.
How does this approach translate into an operational
strategy? First, determine whether the lesion needs SS,
which may be a laborious and time-consuming approach
and should be used only if necessary. We empirically stated
that this approach should be used in lesions 15 mm and,
generally, when the vessel size is not 3.5 mm in size. This
statement is based on the fact that implanting long stents in
vessels with a large angiographic reference vessel size
(3.5 mm) is usually associated with more acceptable
restenosis rates (17).
Second, if the lesion needs SS, the first step is to perform
IVUS to determine the optimal balloon size needed to
perform angioplasty. Intravascular ultrasound is necessary
because these lesions are frequently located in a vessel with
diffuse disease. This situation leads to an underestimation of
the true vessel size when angiography is used to make the
assessment. Dilation of a lesion with an undersized balloon
may lead to a suboptimal result.
Procedural safety. The rate of major procedural complica-
tions in this study does not differ significantly from the
complication rates reported with TS in focal lesions in the
BENESTENT II trial (25). The cumulative incidence of
acute and subacute thromboses in the SS group was 0.8%,
which is as low as that found in any of the major stent trials.
Six-month follow-up outcome. Considering that the le-
sions treated with the IVUS-guided SS approach had a
mean vessel diameter of 2.95 mm and a mean length of
26.5 mm, an angiographic restenosis rate of 25%, a TLR
rate of 19% and a six-month follow-up MACE rate of 22%
represent a considerable improvement in outcome, as com-
pared with the rates reported on the treatment of long
lesions (10–16).
Implications for management of dissections after coro-
nary interventions. Traditionally, dissections after PTCA
have been considered a marker of acute closure or stent
thrombosis (26). However, inducing dissections is an inte-
gral part of lumen enlargement with PTCA, and not all
dissections should be judged to be equal (27). In this study,
final residual angiographic dissections were left untreated in
39% of lesions treated with the SS approach (82% type B).
If the IVUS measurement of the true lumen at the dissec-
tion area was 50% of the vessel CSA, the dissection was
considered as acceptable. If this target was not met, a stent
was implanted at the site of the dissection. Subgroup
analysis of the vessels with untreated dissections in this
study demonstrated no difference in the incidence of adverse
events, including short- and long-term outcomes.
Study limitations. The major limitation of this study is
that it was not a randomized trial. Even if it was accurate,
the matching process may have led to a selection bias. In
addition, we cannot determine the contribution of IVUS,
versus the use of provisional and short stents, to the
improved outcome.
Conclusions. Intravascular ultrasound-guided balloon an-
gioplasty with SS permits safe treatment of long lesions.
Long-term outcomes, including angiographic restenosis and
follow-up MACE, are superior to the outcomes achieved in
the matched group of patients treated with TS and to those
in historical control subjects treated with balloon angio-
plasty alone or TS.
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